2021 – a transformational year for Intravacc
The year 2021 was a transformational year for Intravacc, affecting all levels and departments within the company.
On 1 January 2021, Intravacc became a private entity. We stepped into 2021 as a stand-alone business, transforming from an R&D driven institute towards a full contract development and manufacturing organization (CDMO). As we were all affected by the second year of the COVID-19 pandemic in one way or the other, I am proud and grateful that we still managed to continue our transformation process to ensure our business continuity.
We are delighted with our progress in 2021 and this gives us great confidence to continue to succeed in our mission to become one of the leading CDMO’s within the vaccine and immunotherapy industry and, together with our partners, help to reduce human diseases.
The future: Intravacc’s plans for 2022
In 2022 we will fast track to build a strong commercial and business development team and Intravacc will pursue our efforts of expanding partnerships and service contracts. We will continue to improve our platform technologies and to broaden the use of our technologies outside the field of infectious diseases. The company also expects to reduce its operating expenses and to take a major step forward to optimize its project turnaround time by rolling out a streamlined product development process.
The Board of Directors sincerely thanks all our employees, consultants and scientific advisors, whose continuing contributions enable our success. We want to extend this gratitude to our shareholder, investors, collaborators, the medical community, the Ministry of Health and other stakeholders whose belief and ongoing support have enabled us to make a significant investment in our people, who in turn are ambitious to continue to build Intravacc into a leading CDMO.